The team at MassDevice.com and Drug Delivery Business News will be updating this post periodically as news comes out of ACC 2017, the annual American College of Cardiology meeting in Washington March 17-19.
Boston Scientific touts 3-year outcomes for Synergy bioabsorbable drug-eluting stent
Data presented at ACC 2017 showed that Boston Scientific‘s (NYSE:BSX) Synergy bioabsorbable polymer drug-eluting stent was as efficacious as the company’s Promus Element Plus drug-eluting stent system, with a lower relative rate of stent thrombosis.
The 3-year Evolve II trial enrolled 1,684 patients with native coronary artery lesions and randomized patients to receive either the Synergy or Promus stent. The primary endpoint was target lesion failure at 12 months.
Previous work has demonstrated that drug-eluting stents reduce cardiac events compared with bare metal stents, but researchers also observed that permanent polymers can cause chronic inflammation and increase the risk of later cardiac events.
The Synergy stent is a thin-strut platinum chromium metal alloy coronary stent. It is made of the same metal alloy as the Promus system, except the Synergy device is coated with an ultrathin abluminal bioresorbable polymer which absorbs completely 3 months after drug elution, according to the researchers.
The data showed that the Synergy stent was non-inferior to the Promus stent for target lesion failure at 1 year. At 2 years, target lesion failure was 9.4% and 8.5% for Synergy and Promus, respectively. Adverse events including death and revascularization were not significantly different between the 2 treatment groups, according to the study.
The researchers observed no additional stent thrombosis events with the Synergy stent beyond day 6 through the 2-year follow-up mark.
Researchers concluded that the Synergy stent, which proved to be as effective as the Promus device, exhibited a low stent thrombosis rate at 1 year, 2 year and 3 years post-implantation.
